"The bottom line here is we're likely to have a similar number of total hospitalizations as we had last year," Dylan George, PhD, director of the CDC's Center for Forecasting and Outbreak Analytics, told reporters during a webinar on Wednesday.
Moderna on Wednesday said its combination vaccine targeting Covid and the flu will move to a final stage trial after showing positive results in an earlier study.
The biotech company is hoping its shot, mRNA-1083, can win approval from regulators in 2025.
This vaccine is effective against EG.5, the currently dominant coronavirus strain in the United States, and like Pfizer and Moderna’s mRNA vaccines, it has been updated to target the XBB Omicron subvariant.
Recent Comments